# Instil Bio (TIL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TIL
## Company Profile
- Ticker: TIL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 7.66 USD
- Market cap: 55001825.36 USD
- Last updated: 2026-09-03
## Business Overview
### Therapeutics Acquisition Strategy
Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutics. It is evaluating acquisitions, in-licensing transactions, and related opportunities that could provide access to new drug candidates.
### Portfolio Rebuilding
Following the wind-down of prior internal programs, Instil currently operates without a disclosed active clinical pipeline. Its near-term business model centers on redeploying its organization and capital into externally sourced therapeutic assets.
## Why The Stock Is Moving

As of Sep 3, 2026, TIL closed down 0.33% at $7.66. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-13 21:00 EST — [Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-second-quarter-2026-financial-results-and-provides-corporate--57dfbd2e) — Source: Instil Bio
- 2026-05-15 11:00 EST — [Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-03-27 11:00 EST — [Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-01-06 12:00 EST — [Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco](https://biopharmsignal.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-license-and-collaboration-agreement-with-immuneonco) — Source: Instil Bio
- 2025-11-13 12:00 EST — [Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio